ClariVest Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

ClariVest Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-54,487	Closed	-$2.03M	–	852
2021 Q2	$2.03M	Buy	54,487 +58	+0.1%	+$1.78K	0.07%	216
2021 Q1	$1.39M	Sell	54,429 -1,700	-3%	-$43.4K	0.05%	246
2020 Q4	$1.24M	Sell	56,129 -35,497	-39%	-$782K	0.04%	253
2020 Q3	$1.65M	Sell	91,626 -3,503	-4%	-$72.5K	0.05%	249
2020 Q2	$2.42M	Sell	95,129 -41,344	-30%	-$891K	0.07%	202
2020 Q1	$2.51M	Sell	136,473 -10,985	-7%	-$214K	0.07%	177
2019 Q4	$3.25M	Buy	147,458 +92,158	+167%	+$1.85M	0.07%	189
2019 Q3	$794K	Sell	55,300 -500	-0.9%	-$7.15K	0.02%	368
2019 Q2	$879K	Sell	55,800 -600	-1%	-$8.16K	0.02%	314
2019 Q1	$826K	Buy	+56,400	New	+$648K	0.02%	413

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ClariVest Asset Management's DRNA Position: Q3 2021 in Review

ClariVest Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 54,487 shares — an estimated $2.03M sold.

ClariVest Asset Management first reported a position in DRNA in Q1 2019 and held it in 10 quarters. The position peaked at $3.25M in Q4 2019. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

ClariVest Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
ClariVest Asset Management sold 54,487 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $2.03M.
ClariVest Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 10 quarters.
ClariVest Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $3.25M in Q4 2019.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on ClariVest Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.